Lipella Pharmaceuticals
Pittsburgh
About Lipella Pharmaceuticals
Lipella Pharmaceuticals is a biotechnology company that develops products for intravesical therapy. It is a method of providing local treatments directly to the urinary bladder lumen via urethral catheterization. Indications they target include interstitial cystitis (also known as painful bladder syndrome), overactive bladder, and superficial bladder cancer. Interstitial cystitis is a chronic, painful, inflammatory condition of the bladder wall that affects over 1 million people in the United States. Its cause is unknown and there is no cure. Treatment options exist, but a majority of cases are refractive to existing therapies.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 1 – 10
- Estimated revenue: Less than $1M
- Total funding: $13.0M
- Funding stage: IPO
- Last round: Post-IPO Equity (Mar 2025)
- Ticker: nasdaq:LIPO
- Website: lipella.com
- Phone: 1-412-894-1853
Industries & Categories
Biotechnology, Developer Platform, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/lipella-pharmaceuticals-35296 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.